Paolo Fornara

Paolo Fornara

Auto-generated profile, based on publicly available information

Paolo Fornara

University Hospital Halle (Saale), Halle, Germany

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2009 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
SWSigrid Wagner
Sigrid Wagner
FGFrancesco Greco
Francesco Greco
AIAntonino Inferrera
Antonino Inferrera
MHM. Raschid Hoda
M. Raschid Hoda
FKFelix Kawan
Felix Kawan
PFPaolo Fornara
Paolo Fornara

1 March 2009 in European Urology
Verified
Journal Article
Closed access
SWSigrid Wagner
Sigrid Wagner
FGFrancesco Greco
Francesco Greco
AHAmir Hamza
Amir Hamza
RHRashid M. Hoda
Rashid M. Hoda
HHHans Jürgen Holzhausen
Hans Jürgen Holzhausen
PFPaolo Fornara
Paolo Fornara

1 April 2006 in Transplantation Proceedings
Verified
Journal Article
Closed access
HLH. Loertzer
H. Loertzer
JSJ. Soukup
J. Soukup
AHAmir Hamza
Amir Hamza
AWA. Wicht
A. Wicht
ORO. Rettkowski
O. Rettkowski
PFP. Fornara
P. Fornara

23 July 2010 in BJU International
Verified
Journal Article
Closed access
PDF file
FGFrancesco Greco
Francesco Greco
SWSigrid Wagner
Sigrid Wagner
MHM. Raschid Hoda
M. Raschid Hoda
FKFelix Kawan
Felix Kawan
AIAntonino Inferrera
Antonino Inferrera
PFPaolo Fornara
Paolo Fornara

1 October 2018 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
Thomas GreitherThomas Greither
Thomas Greither
KFKersten Fischer
Kersten Fischer
GTGerit Theil
Gerit Theil
MMMarios Marcou
Marios Marcou
HHHans-Juergen Holzhausen
Hans-Juergen Holzhausen
VLVerena Lieb
Verena Lieb
Background: GP88/Progranulin is a well-recognized cell growth promoter in different cancers, and elevated serum GP88 levels have been described as negative prognostic factor in breast cancer. However, serum levels in prostate cancer (PCa) patients have not yet been studied. Material and Methods: We analyzed serum GP88 levels by enzyme immunosorbent assay and correlated them with clinicopathological parameters in PCa patients. PCa patients were separated into two groups based on the serum GP88 median level (low ≤44.56 ng/mL or high >44.56 ng/mL) and according to their median age (younger ≤66 years or elder patients >66 years). Results: Low serum GP88 levels were more often detected in younger patients and high levels in elder patients (P=0.018; Fisher’s exact test). PCa patients were separated into three groups, Gleason score (GS) ≤6; GS=7; and GS≥8. In receiver operating characteristic analyses, we could distinguish GS≤6 from GS=7 [area under the curve (AUC): 0.646; P=0.018] and GS≤6 from GS≥8 (AUC: 0.629; P=0.048) but not GS=7 from GS≥8. For survival analysis, GP88 levels were separated into two groups by an optimized cutoff value of 36.92 ng/mL. Using this GP88 stratification, all PCa patients and younger patients with a low serum GP88 level had a significantly better overall survival compared with patients with higher serum GP88 levels (log-rank test P=0.010 and P=0.024). Conclusion: Serum GP88 levels are significantly different depending on age and GS, and they are associated with the prognosis of PCa patients.

1 February 2001 in Oncology Research and Treatment
Verified
Journal Article
Closed access
HLH.-J. Luboldt
H.-J. Luboldt
ASA. Swoboda
A. Swoboda
CBC. Börgermann
C. Börgermann
PFP. Fornara
P. Fornara
HRH. Rübben
H. Rübben
Measurement of serum prostate-specific antigen (PSA) is widely used as an aid in early detection of prostate cancer. Most patients with prostate cancer and a PSA level less than 10.0 ng/ml have early-stage disease. Thus, the detection of prostate cancer in its potentially curable stages requires the use of low PSA cutoffs, inevitably leading to many unnecessary biopsies. The combined use of free PSA and total PSA increases specificity of early detection. To develop risk assessment guidelines and a cutoff value of ratio of free (f) to total (t) PSA with a high predictive value for prostate cancer in men to whom the test would be applied in real life practice, a multicenter early detection trial was initiated. In one week in November 1997, 963 urologists prospectively examined 11,644 men between 45 and 75 years by digital rectal examination (DRE) and prostate-specific antigen with 4.0 ng/ml as cutoff. Data of physical examination were collected by questionnaire. At this time participants were not aware of their PSA values. Suspicious findings were further investigated with sextant biopsy. Prostate volume was determined with transrectal ultrasound (TRUS). Different cutoff levels were correlated to age and detection rate. From1,115 biopsied men, the data of 633 men fulfilled the criteria DRE-negative, TRUS-estimated volume, and PSA 4.0-10.0 ng/ml. In that cohort 91 cancers were detected. Percentage of fPSA was significantly more predictive of cancer than tPSA (p < 0.001). The area under the ROC curve was 0.72 for percent fPSA (% fPSA) and 0.62 for total PSA. The cancer risk nearly doubled using a cutoff of 10% fPSA, the median %PSA level of the detected cancers. A better discrimination of cancer and noncancer especially in the age group above 70 years is possible. Using a cutoff of 16% fPSA increases positive predictive value (PPV) to 25% missing only 4% of cancers. Nearly 45% of the biopsies could be avoided. In the age group 45-69 years, a cutoff of 20% fPSA leads to PPV of 15%, missing 6% of cancers. Unnecessary biopsies could be avoided in 12%. Using % fPSA in early detection of prostate cancer reduces the number of unnecessary biopsies, especially in men with negative rectal examination in the PSA range of 4.0-10.0 ng/ml. In order to diminish biopsy rate in men 70 years or older a cutoff of 16% fPSA should be used. A cutoff of 20% fPSA in men younger than 70 years is recommended to increase sensitivity in that age group.